Immune Pharmaceuticals Inc. (IMNP) Stock News
NASDAQ:IMNP - Nasdaq -
IMNP Latest News, Press Relases and Analysis
Wired News – Johnson & Johnson to Pay Compensatory Damages over Claims Linking Cancer to Asbestos in Talc
Mentions: JNJ
Technical Snapshots for These Drug Makers Stocks -- Immune Pharma, Zogenix, Shire, and AbbVie
Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on July 25) Allakos Inc (NASDAQ: ALLK)(...
Benzinga's Daily Biotech Pulse: FDA Greenlights Tandem Diabetes' Insulin Pump, More IPOs On Tap
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 21) Aerie Pharmaceuticals Inc (...
Maxim Group Thinks Immune Pharmaceuticals’ Stock is Going to Recover
Maxim Group analyst Jason McCarthy assigned a Buy rating to Immune Pharmaceuticals (NASDAQ: IMNP) today and set a price target of $3. The company’s shares closed yesterday at $0.57, close to its 52-week low of $0.50. McCarthy observed: “Bertilimumab is a monoclonal antibody (mAb) targeting eotaxin-1, a chemokine implicated in multiple inflammatory diseases including bullous
The post Maxim Group Thinks Immune Pharmaceuticals’ Stock is Going to Recover appeared first on Analyst Ratings.
Immune Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides a Corporate Update